PTC THERAPEUTICS, INC. (PTCT): debt financing — PTC Therapeutics closes $550M zero-coupon convertible notes offering, repurchases $222M of existing notes

PTC THERAPEUTICS, INC.

Issued $550M aggregate principal of 0.0% Convertible Senior Notes due 2031, initial conversion price ~$107.48/share.
Net proceeds approximately $535.5M after discounts and estimated offering expenses.
Using ~$328.8M to repurchase $222M principal of existing 1.50% Convertible Senior Notes due 2026; $55.5M remains outstanding.
Notes are general unsecured senior obligations; company may redeem after June 20, 2029 if stock price >=130% of conversion price.
Initial purchasers exercised in full their option to purchase an additional $50M of notes.

item 1.01 item 2.03 item 3.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

PTC THERAPEUTICS, INC. incurred convertible notes of $550,000,000 with U.S. Bank Trust Company, National Association at 0.0% maturing June 15, 2031.

Instrument: convertible notes
Principal: $550,000,000
Counterparty: U.S. Bank Trust Company, National Association
Rate: 0.0%
Maturity: June 15, 2031
Event: incurrence

Exact text from the filing

On June 18, 2026, PTC Therapeutics, Inc. (the “Company”) completed its previously announced private offering of $550,000,000 aggregate principal amount of its 0.0% Convertible Senior Notes due 2031 (the “Notes”) and entered into an indenture with U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), governing the Notes (the “Indenture”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

PTC THERAPEUTICS, INC. entered into Indenture with U.S. Bank Trust Company, National Association valued at $550,000,000 0.0% Convertible Senior Notes due 2031 (effective 2026-06-18).

Action: entry
Agreement: notes offering
Counterparty: U.S. Bank Trust Company, National Association
Value: $550,000,000 0.0% Convertible Senior Notes due 2031
Effective: 2026-06-18

Exact text from the filing

On June 18, 2026, PTC Therapeutics, Inc. (the “Company”) completed its previously announced private offering of $550,000,000 aggregate principal amount of its 0.0% Convertible Senior Notes due 2031 (the “Notes”) and entered into an indenture with U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), governing the Notes (the “Indenture”).

View on SEC.gov

225 debt financings filed in the last 30 days. Browse all debt financings →

PTC THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-26-075731

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.